Here are the 10-K annual reports from ICU Medical Inc (ICUI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ICUI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUI filings page.
ICU Medical describes its 2025 business, strategy and risks as a global provider of infusion therapy, vascular access and vital care products. The company now operates through Consumables, Infusion Systems and Vital Care, selling to hospitals, distributors and alternate‑site providers in more than 100 countries.
ICU highlights the 2022 acquisition of Smiths Medical and the 2019 Pursuit Vascular deal, as well as a 2025 transaction forming a joint venture with Otsuka, under which it sold 60% of its IV Solutions business while retaining 40% and commercial responsibilities. Management emphasizes ongoing R&D investment, strong regulatory oversight in the U.S. and EU, and risks from inflation, foreign exchange, trade policy, FDA compliance, cybersecurity, supplier concentration and high leverage from the Smiths Medical acquisition.